Media headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7125179658143 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Regeneron Pharmaceuticals (REGN) traded down $1.30 during trading hours on Friday, hitting $366.96. 830,679 shares of the stock traded hands, compared to its average volume of 782,990. The firm has a market cap of $39,430.00, a PE ratio of 33.33, a PEG ratio of 1.45 and a beta of 1.52. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a one year low of $340.09 and a one year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 EPS. sell-side analysts forecast that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.

REGN has been the subject of a number of analyst reports. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 31st. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a research report on Thursday, November 16th. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Guggenheim reissued a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $471.11.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals (REGN) Getting Somewhat Positive News Coverage, Study Shows” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-getting-somewhat-positive-news-coverage-study-shows/1804904.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.